Files
Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/54603
Rapid improvement of canine cognitive dysfunction with immunotherapy designed for Alzheimer's disease
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Immunotherapy against amyloid-β(Aβ) may improve rodent cognitive function by reducing amyloid neuropathology and is being validated in clinical trials with positive preliminary results. However, for a complete understanding of the direct and long-term immunization responses in the aged patient, and also to avoid significant side effects, several key aspects remain to be clarified. Thus, to investigate brain Aβ clearance and Th2 responses in the elderly, and the reverse inflammatory events not found in the immunized rodent, better Alzheimer"s disease (AD) models are required. In the aged familiar canine with a Cognitive Dysfunction Syndrome (CDS) we describe the rapid effectiveness and the full safety profile of a new active vaccine candidate for human AD prevention and treatment. In these aged animals, besidesa weak immune system, the antibody response activated a coordinated central and peripheral Aβ clearance, that rapidly improved their cognitive function in absence of any side effects. Our results also confirm the interest to use familiar dogs to develop innovative and reliable therapies for AD.
Subject (English)
Citation
Citation
BOSCH, Maria Neus, et al. Rapid improvement of canine cognitive dysfunction with immunotherapy designed for Alzheimer's disease. Current Alzheimer Research. 2013. Vol. 10, num. 5, pags. 482-493. ISSN 1567-2050. [consulted: 14 of June of 2026]. Available at: https://hdl.handle.net/2445/54603